Finoriq research workspace
ACTUATE THERAPEUTICS, INC. (ACTU) News
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the. Review ACTU recent headlines, source links, and company news on Finoriq.
Company Snapshot
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Company
- ACTUATE THERAPEUTICS, INC. (ACTU)
- Ticker
- ACTU
- Market Cap
- $33.4M
- Latest Price
- $1.395
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.